Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
1833.HK(1833.HK) - Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025...
Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth
1833.HKHONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained...
Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth
1833.HKHONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained...
Ping An Good Doctor (1833.HK) Reports Strong Interim Results: Revenue and Profit Accelerate as AI Fuels New Growth Momentum
1833.HKHONG KONG, Aug. 19, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025. During the first half of 2025, the Company delivered steady...
Ping An Good Doctor (1833.HK) Reports Strong Interim Results: Revenue and Profit Accelerate as AI Fuels New Growth Momentum
1833.HKHONG KONG, Aug. 19, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025. During the first half of 2025, the Company delivered steady...
